Antimicrobial Resistance – OECD

 

Antimicrobial resistance (AMR) is a complex issue of global concern with potentially dramatic health and economic consequences.

The OECD provides countries with the evidence to implement effective and cost-effective One Health policies to tackle AMR, promote effective use of antimicrobials in human and animal health, strengthen infection prevention and control measures, and incentivise research and development in the antibiotic sector.

LATEST EVENT – HIGH-LEVEL ONE HEALTH MINISTERIAL CONFERENCE ON ANTIMICROBIAL RESISTANCE

AMR-ECDC-Policy-Brief-2022

High-Level One Health Ministerial Meeting On Antimicrobial Resistance, French Presidency of the EU Council
Paris, France – March 7, 2022

The OECD, in collaboration with the European Centre for Disease Prevention and Control, the European Food Safety Authority and the European Medicines Agency, has produced a briefing note on antimicrobial resistance (AMR) in the European Union and European Economic Area. It presents trends in antibiotic consumption and AMR from a One Health perspective, and sets out policy options for national governments and the European Union.

Key documents on antimicrobial resistance

G7 WORK ON AMR

The G7 has consistently committed to tackling global health challenges, including the fight against infectious diseases, and positioned itself as a leading partner in reaching health-related Millennium Development Goals, by initiating and supporting many global instruments of response to threats posed by infectious diseases. The findings presented in this report show that there is a strong case for G7 action in the area of AMR.

G20 WORK ON AMR

Read the note prepared for the G20 by OECD along with WHO, FAO and OIE, on potential strategies to tackle antimicrobial resistance (AMR) and ensure sustainable research and development (R&D) for new antibiotics. The note calls for action based on a coordinated and cross-sectoral approach under the ‘One Health’ framework, highlights the urgent need to address barriers to innovation and suggests policy and governance mechanisms to reactivate the antibiotic R&D pipeline.

In the Hamburg G20 declaration, leaders called for a new R&D Collaboration Hub and committed to further examine practical market incentive options, in collaboration with relevant experts including from the OECD and the WHO.
 

FURTHER READING

CONTACT

For more information, please contact [email protected]

‌ Small follow us Twitter icon‌ 
Follow us on Twitter @OECD_Social

 

 

Read original article here

Denial of responsibility! News Smashers is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

DMCA compliant image

Leave A Reply

Your email address will not be published.